Boston Scientific
Advancing science for life™

RANGER™

Paclitaxel-Coated PTA Balloon Catheter

Clinically Proven in both randomized and real-world trials

REVELUTIONIZE
YOUR PRACTICE

RANGER™ DCB has been studied in over 250 patients, in both randomized and real-world clinical trials

RANGER SFA
RANDOMIZED CONTROLLED TRIAL

6 months

2:1 DCB/PTA N=105
Avg Lesion Length
68 mm

The Ranger SFA-Trial has achieved among the highest FTLR of 94.4% at 6 months, with significantly less late lumen loss vs. PTA

94.4%
Freedom from TLR vs. 88% PTA



RANGER ALL COMERS*
REGISTRY

N=149
Avg Lesion Length
135 mm

The Ranger All-Comers Registry confirms benefit of an efficient drug coating technology in challenging, real-world lesions

91.9%
Freedom from TLR**

91.1%
Primary Patency**

*Interim analysis at 6 months of 149 patients
**Kaplan Meier Estimate

REVELUTIONIZE
YOUR PRACTICE

RANGER™ Clinically Proven in both randomized and real-world trials

RANGER SFA TRIAL

6 months

2:1 DCB/PTA N=105
Avg Lesion Length
68 mm

Design
Level 1 evidence trial:
- Randomized, controlled trial
- Multicenter, 10 centers in Europe
- External, blinded core lab adjudication

Baseline Characteristics
Average lesion length: 68 mm
Diabetes: 39 %
Moderate & Severely Calcified: 60 %
Total occlusion: 34 %
Percent diameter stenosis: 85 %

Efficacy Results
Late Lumen Loss was significantly less for Ranger DCB than for control (P = 0.0017) → Primary endpoint was met

Safety Results
Similar Adverse Event and Serious Adverse Event rates between groups
- No target limb amputations
- 1 death within 6 months (control group)

Freedom from TLR rate through 6 months:
88 % control vs 94.4 % Ranger (P = 0.47)

Freedom From TLR at 6 Months*



*Kaplan-Meier analysis

RANGER REGISTRY

N=149
Avg Lesion Length
135 mm

Design
Multicenter registry, with planned enrollment of 180 patients

Baseline Characteristics
Average lesion length: 135 mm
Diabetes: 34 %
Rutherford: 80 % Class III & higher
TASC C&D: 59 %
Percent diameter stenosis: 91 %

Safety & Efficacy results at 6 months
91.9 % Freedom from TLR
91.1 % Primary Patency

Freedom From TLR at 6 Months*



*Kaplan-Meier estimate

80% of patients improved ≥2 Rutherford categories at 6 months



REVELUTIONIZE
YOUR PRACTICE

CONCLUSION

The Ranger DCB has been studied in over 250 patients, in both randomized and real-world clinical trials.

The Ranger SFA-RCT has achieved among the **highest FTLR of 94.4% at 6 months,** with significantly less late lumen loss vs. PTA.

The Ranger All-Comers Registry confirms benefit of an efficient drug coating technology in challenging, real-world lesions with FTLR of 91.9%* and Primary Patency of 91.1%*.

*Kaplan-Meier estimate

Ranger All-Comers Registry, Interim analysis at 6 months of 149 patients.
Sponsored by Klinikum Arnsberg, M. Lichtenberg and the SFA Registry Investigators, CIRSE 2016.
Ranger SFA RCT presented at CIRSE 2016 by Prof Scheinert, Principal Investigator.
Ranger™ Paclitaxel-Coated PTA Balloon Catheter is manufactured by Hemoteq AG and distributed by Boston Scientific Corporation.

PI-426103-AA Sept 2016 Printed in Germany by medicalvision.

Boston Scientific
Advancing science for life™

www.bostonscientific.eu